Dr. Zhou received her PhD in Stem Cell Biology from the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, and she completed her postdoctoral fellowship in Stem Cell Biology at Weill Cornell Medicine. As the Director of the Stem Cell Research Facility at the MSKCC, she is fully focused on establishing a hPSC-based research facility with a mission of sharing stem cell expertise and resources. Dr. Zhou was a pioneer in establishing a protocol for using human urinary cells as a source to generate iPSCs in a noninvasive manner. Utilizing this protocol, she developed a panel of iPSC models for studying premature aging and cardiovascular diseases. She has also combined the hPSC technology with chemical screens and the latest genome editing technologies such as prime editing, base editing, and CRISPR/Cas9 based knock-out and knock-in in hPSCs for her own research and collaboration projects. Her group continually refines and adapts the latest technologies relevant to hPSC research including genetic manipulation, directed differentiation, trans-differentiation and reprogramming, and offer them to the basic and clinical researchers in the community.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ting Zhou discloses the following relationships and financial interests:
-
Cell Press
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures